Note R – Subsequent Events	6 Months Ended
Jun. 30, 2011
Subsequent Events [Text Block]	NOTE R – SUBSEQUENT EVENTS TARSA As described more fully in Note J, on July 8, 2011, we, along with the founding investors of Tarsa, entered into another Purchase Agreement with Tarsa and we invested an additional $1,301,000 in Tarsa convertible promissory notes and warrants. Subject to the prior approval of our Board of Directors and the consent of Victory Park, we will have the right to purchase additional convertible promissory notes with an aggregate original principal amount of $650,571 and additional warrants to purchase up to an aggregate of 67,435 shares of Series A Preferred Stock at a Subsequent Closing on the date the three founding investors may elect for the closing to occur, if any. GSK On August 3, 2011, we entered into a Development Services and Clinical Supply Agreement with GSK. Under the terms of the agreement, we will receive up to approximately $2.2 million in milestone payments from GSK to undertake certain development and manufacturing activities related to the active pharmaceutical ingredient and finished drug product of an oral formulation of a recombinantly produced investigational PTH analog for the treatment of osteoporosis in postmenopausal women in advance of GSK’s potential decision to study the molecule in a Phase 3 study.

Note R – Subsequent Events

6 Months Ended

Jun. 30, 2011

NOTE R – SUBSEQUENT EVENTS

TARSA

As described more fully in Note J, on July 8, 2011, we, along with the founding investors of Tarsa, entered into another Purchase Agreement with Tarsa and we invested an additional $1,301,000 in Tarsa convertible promissory notes and warrants. Subject to the prior approval of our Board of Directors and the consent of Victory Park, we will have the right to purchase additional convertible promissory notes with an aggregate original principal amount of $650,571 and additional warrants to purchase up to an aggregate of 67,435 shares of Series A Preferred Stock at a Subsequent Closing on the date the three founding investors may elect for the closing to occur, if any.

GSK

On August 3, 2011, we entered into a Development Services and Clinical Supply Agreement with GSK. Under the terms of the agreement, we will receive up to approximately $2.2 million in milestone payments from GSK to undertake certain development and manufacturing activities related to the active pharmaceutical ingredient and finished drug product of an oral formulation of a recombinantly produced investigational PTH analog for the treatment of osteoporosis in postmenopausal women in advance of GSK’s potential decision to study the molecule in a Phase 3 study.